We conduct research in the following areas:• pharmacoepidemiology using large electronic health record datasets and disease registers
• identification and prevention of adverse drug events
• adherence to medication and related to health outcome
• disease epidemiology (breast cancer, cardiovascular disease)
• population health and health services research
• health behaviour change methods
We work with healthcare professionals, regulatory authorities, decision makers, researchers and patient representatives to address research questions and evidence of most relevance at the population level. Our backgrounds are in pharmacy, statistics, psychology, epidemiology, health service research and translational medicine.Our research is currently funded by the Health Research Board, Research Leaders Award (RL-15-1579), KEDs award (KED-17-012) and an Applied Partnership Award (APA-2017-0015).
About EMeRGe and our Mission
EMeRGe is an epidemiology research group led by Prof Kathleen Bennett at RCSI, Dublin.
The main pillars of research within EMeRGe include:
Safe and Quality Medicines
Other disease modelling
Here at EMeRGe, our mission is to improve population health outcomes through research evidence and to translate the evidence into effective decision making for policy and practice. In particular, to: promote safe, quality and effective medicines management and model disease epidemiology in cancer and cardiovascular disease.Click Here to Discover More About Emerge
There are four main pillars of research within the EMeRGe research group.Click on the icons to find our more about our research areas.
Safe & Quality Medicines
Prescribing of medicines is the most common healthcare intervention. Our research provides data and evidence on population based estimates and risk prediction of adverse drug events (ADEs) in the primary and secondary care settings. It includes the ADAPT study which is a prospective study examining the prevalence of ADRs in hospital admissions following an adverse drug event. It also includes research using large epidemiological studies of high risk medicines and associated outcomes.
Other Disease Modelling
Modelling the underlying disease process and associated outcomes can help inform policy and practice by providing evidence on the potential effectiveness of interventions, or projected long term trends for planning. Previous research in this area has been in coronary heart disease (CHD IMPACT model) and the impact of health policies on influencing health determinants.
Meet Our Team
Meet our Team, Collaborators, Partners and Intenational Advsiory Committee.Our PartnersOur CollaboratorsIntenational Advsiory Committee
Prof. Kathleen Bennett
Associate Professor in PharmacoepidemiologyRead More
Dr Caitriona Cahir
Research FellowRead More
Prof. Anne Hickey
Head of the Division of Population Health Sciences (PHS)Read More
Dr Maeve Mullooly
Research FellowRead More
Dr Bernadine O’Donovan
Dr Jonathan Briody
Postdoctoral researcherRead More
Dr Mengyang Zhang
General Public Information
Here you will find excellent eduactional material and resources related to Emerge Research
Stay up to date with all the latest new from Emerge
‘Know Check Ask’ campaign – invitation to participate in research The WHO has a Global Patient Safety Challenge ‘Medication without harm’ to reduce harm associated with medicines by 50%[…]Read more
Explaining the fall in Coronary Heart Disease mortality in the Republic of Ireland between 2000 and 2015 – IMPACT modelling study. Read more – https://www.internationaljournalofcardiology.com/article/S0167-5273(19)34157-9/pdfRead more